## UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Commissioner of Patents Box Patent Application Washington, D.C. 20231 Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO .: CA2295US NP

INVENTORS: Alan J. Collis et al

TITLE: HETEROARYL-CYCLIC ACETALS I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231,

**PATEN** 

may	31	2001
Date of Deposit		1
Bon	air	Aden
Signature		
EL 816	575931	US
Express Mail No.		

ADDI	IC ATION	MENTS

APPLICATION ELEMENTS								
1.	$\boxtimes$		Transmittal Form (e.g., PTO/SB/17) nit an original and a duplicate for fee processing)					
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Birdf Summary of the Invention - Birdf Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure		Total Pages	55			
3.		Draw	ring(s) (35 U.S.C. 113)	Total Sheets	0			
4.	Oath a.	or De	eclaration Newly unexecuted	Total Pages	2			
	b.	Copy from a prior application (37 CFR § 1.63(d)) (for continuation/divisional with Box 16 completed)						
		i. DELETION OF INVENTOR(S)  Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).						
5.		Microfiche Computer Program (Appendix)						
6.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies							

	If a CONTINUING Application, check appropriate box, and supply the requisite information:  Continuation Divisional Continuation-in-part of prior application no: PCT /GB99/04285, filed December 16, 1999, Examiner , Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).
$\boxtimes$	This application claims the benefit of GB Application No. 9827721.3, filed December 16, 1998, and U.S. Provisional Application No. 60/122,425, filed March 2, 1999. (The cross reference has been/will be inserted on page one of the specification).
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
ACC	OMPANYING APPLICATION PARTS
7. 8. 9. 10. 11. 12. 13. 14.	Assignment Papers (cover sheet & document(s))  37 CFR §3.73(b) Statement Power of Attorney  English Translation Document (if applicable)  Information Disclosure Copies of IDS Statement (IDS)/PTO-1449  Preliminary Amendment  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  "Small Entity Statement(s) Statement filed in prior application, Status still proper and desired  Certified Copy of Priority Document(s) (if foreign priority is claimed)  Other: EFS Print
COF	RRESPONDENCE ADDRESS
$\boxtimes$	Customer Number or Bar Code Label  (Insert Customer No or Attach bar code label here)  (Invinty Newman), Reg No. 22,638
Pate Rou Mail Brid	Attorney/Agent for Aphlicant htis Pharmaceuticals Inc. int Department te #202-206 / P.O. Box 6800 Code: EMC-G1 gewater, New Jersey 08807-0800 phone (908) 231-2785 fax (908) 231-2626

Aventis Docket No. CA2295US NP

09871554.053101

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE collection of information unless it disables a solid OMB control number Complete if Known

Application Number

TBD

## **FEE TRANSMITTAL** ta" EV 2004

		Filing Date	Concurrently herewith	
for FY 20	01	First Named Inventor	Alan J. Collis et al	
Patent fees are subject to annual revision.		Examiner Name	TBD	
,,		Group / Art Unit	TBD	
TOTAL AMOUNT OF PAYMENT	(\$) 710	Attorney Docket No.	CA2295US NP	

METHOD OF PAYMENT FEE CALCULATION (continued)						
The Commissioner is hereby authorized to charge	3. AE	DITIO				
indicated fees and credit any overpayments to:		Large		Small		
Deposit Account 18-1982 Number	Fee Code	Entity Fee (\$)	Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
Deposit Account Name Aventis Pharmaceuticals Products Inc.	105	130	205	65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or	
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17  Applicant claims small entity status.	127 139	50 130	227 139	25 130	cover sheet Non-English Specification	
See 37 CFR 1 27	147	2,520	147	2,520	For filing a request for reexamination	
2. Payment Enclosed: Check Credit Card Money Order Other	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	1	***	215	55	Extension for reply within first month	
Large Entity Small Entity Fee Fee Fee Fee Description Fee	115 116	110 390	216	195	Extension for reply within second month	
Code (\$) Code (\$) Paid	117	890	217	445	Extension for reply within third month	-
101 710 201 355 Utility filing fee 710 106 320 206 160 Design filing Fee	118	1,390	218	695	Extension for reply within fourth month	<b>—</b>
106 320 206 100 Designing fee	128	1.890	228	945	Extension for reply within fifth month	-
\$68 710 208 355 Reissue filing fee	119	310	219	155	Notice of Appeal	
14 150 214 75 Provisional filing fee	120	310	220	155	Filing a brief in support of an appeal	
3	121	270	221	135	Request for oral hearing	
SUBTOTAL (1) (\$)/10 25 EXTRA CLAIM FEES	138	1,510	138	1,510	Petition to institute a public use proceeding	
Fee Extra from Fee	140	110	240	55	Petition to revive - unavoidable	
Claims   Claims   Delow   Paid   Claims   Clai	141	1,240	241	620	Petition to revive - unintentional	
ndependent 2 - 3**= 0 x = 0	142	1,240	242	620	Utility issue fee (or reissue)	
Claims	143	440	243	220	Design issue fee	
Aultiple Dependent = 0	144	600	244	300	Plant issue fee	
Large Entity Small Entity Fee Fee Fee Fee	122 123	130 50	122 123	130 50	Petitions to the Commissioner Petitions related to provisional applications	
Code         (\$)         Code         (\$)         Fee Description           103         18         203         9         Claims in excess of 20	126	180	126	180	Submission of Information Disclosure Stmt	
102 80 202 40 Independent claims in excess of 3	581	40	581	40	Recording each patent assignment per property (times number of properties)	
104 270 204 135 Multiple dependent claim, if not paid	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
109 80 209 40 "Reissue independent claims over original patent	149	710	249	355	For each additional invention to be examined (37 CFR § 1 129(b))	
110 18 210 9 **Reissue claims in excess of 20 and over onginal patent	179	710	279	355	Request for Continued Examination (RCE)	
	169	900	169	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$)0	Other fe	e (specify)	, —			1
*^or number previously paid, if greater, For Reissues, see above	*Reduc	ed by Basi	c Filing Fe	e Paid	SUBTOTAL (3) (\$)	

SUBMITTED BY Complete (If applicable)						plicable)
Name (Print/Type)	Irving/Newman, Reg. M	. 22,638	Registration No. (Attorney/Agent)	22,638	Telephone	(908) 231-2785
Signature	Chi T	ame			Date	5/30/01
	1 /2					. ,